Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Drug review

- PMLiVE

FDA gives Rare Paediatric Disease designation to Satellite Bio for urea cycle disorders

The mortality rates of UCDs exceeds 25%, with no curative treatment available for newborns

- PMLiVE

Personalization, automation and actionable intelligence: How to achieve purposeful innovation in healthcare communications

By Aaron Fletcher

Amiculum

- PMLiVE

A simplified three-step process for achieving the fundamentals of omnichannel engagement in pharma: how to deliver impactful, connected experiences

By Aaron Fletcher

Amiculum

- PMLiVE

BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma

This type of cancer is the most common one diagnosed in teenagers

- PMLiVE

HRW Wins 2026 Artificial Intelligence Excellence Award in the Pharmaceutical Category

Healthcare Research Worldwide (HRW) has been named a winner in the 2026 Artificial Intelligence Excellence Awards in the Pharmaceutical category, recognizing its innovative use of AI to deliver real-world impact....

Healthcare Research Worldwide

- PMLiVE

Amiculum meets Paul Tunnah: Pharma’s adoption of AI in healthcare communications

By Steve Wilson

Amiculum

- PMLiVE

Smarter Learning and Better Outcomes: How AI Can Provide an Advantage in Medical Education

See how AI-powered patient avatars allow physicians to test complex diagnoses and treatment plans in a simulated environment.

Impetus Digital

- PMLiVE

US FDA launches ultra-rare diseases framework

The draft guidance specifically discusses genome editing and RNA-based therapies

- PMLiVE

PureTech’s deupirfenidone gets FDA and EC Orphan Drug Designations for idiopathic pulmonary fibrosis

Rare diseases are defined as conditions affecting fewer than 200,000 people in the US or fewer than five in 10,000 individuals in the European Union

- PMLiVE

Diabeloop’s DBLG2 receives FDA and CE clearance for automated insulin delivery without meal input

While a lack of meal announcements can lead to lower glycaemic control, it reduces the mental burden for those with type 1 diabetes

- PMLiVE

AI, Agility, and Connected Impact at Alliance 2026

Join the Medscape team in Atlanta, February 16–19, 2026, as Alliance celebrates 50 years of excellence in continuing education for health professionals. We’re bringing our 3 decades of experience in...

Medscape Education

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links